Multiple Myeloma

Implementation of a pharmacist on the healthcare team can have significant clinical and economic benefits. Read More ›

Updated results from a phase 1 trial of subcutaneous isatuximab via OBDS continue to demonstrate an excellent local tolerability with comparable efficacy. Read More ›

Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy. Read More ›

Data from a subgroup analysis of CANDOR supported the efficacy of daratumumab plus carfilzomib and dexamethasone in RRMM, even in high-risk patients. Read More ›

A phase 1 trial of GC012F demonstrated an overall response rate of 100% in high-risk, transplant-eligible patients with newly diagnosed multiple myeloma. Read More ›

In 2022, the COVID-19 pandemic continues to impact the practice of medicine and the dissemination of treatment advances presented in scientific forums. Read More ›

Longer follow-up results of the phase 2 GRIFFIN trial demonstrated that the addition of daratumumab to RVd induction/consolidation in conjunction with ASCT, followed by 24 months of daratumumab-lenalidomide maintenance resulted in deep and durable responses, including stringent CR and MRD negativity rates, in patients with transplant-eligible NDMM. Read More ›

Results of the 18-month follow-up of the phase 1b/2 CARTITUDE-1 trial indicated that a single infusion of cilta-cel produced early, deep, and durable responses in heavily pretreated patients with RRMM, with manageable toxicity. Read More ›

These results indicate that quadruplet induction therapy with daratumumab plus carfilzomib, lenalidomide, and dexamethasone (D-KRd); ASCT; and MRD response–adapted D-KRd consolidation therapy yielded high MRD negativity rates in patients with NDMM. Read More ›